Patent US5481621A successfully refreshed from Google Patents.
Patent US6156347A successfully refreshed from Google Patents.
US6156347A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled release chromium picolinate
Assignee: Bio Dar Ltd
•
Filing: 1998-01-21
•
Granted: 2000-12-05
•
Expires: 2018-01-21
Abstract
Abstract The present invention relates to controlled/extended release oral dosage forms of chromium picolinate. Chromium picolinate is a common and effective biologically active form of chromium. As such, it has beneficial nutritional and therapeutic effects including improved insulin metabolism and lipid lowering activity. The controlled dosage form of the present invention can be provided in various ways, including matrix formulations such as matrix tablets or multiparticulate formulations like micro capsules or coated pellets put into hard gelatin capsules. This provides effective drug delivery for extended periods of time, at relatively stable, optimal plasma peak values, with minimal undesirable side effects. The invention provides effective controlled/extended release oral dosage formulations of chromium picolinate and processes for their preparation.
Inventors
- 👤 Yoav Blatt
- 👤 Oded Friedman
- 👤 Eugene Kimelman
- 👤 Avner Rotman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 15:40
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/555; A61K31/395; A61K31/435; A61K31/44; A61K31/4402; A61K33/00; A61K33/24; A61K9/00; A61K9/48; A61K9/50; A61K9/5073; A61K9/5078
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
97 words
A formulation for controlled/extended release of Chromium Picolinate characterized in that the total in vitro dissolution time determined according to USP XXI paddle method at 50 or 100 rpm is between 6-24 hours for at least 80% of the Chromium Picolinate content, said formulation comprising spherical or irregular particles of Chromium Picolinate coated with a mixed polymer film comprising a water soluble polymer and a water insoluble polymer in a ratio that produces a substantially zero order linear release pattern of active ingredient, wherein the Chromium Picolinate content is between 1 to 80% on a weight/weight basis.
Claim 2
Dependent Claim
97 words
A formulation for controlled/extended release of Chromium Picolinate characterized in that the total in vitro dissolution time determined according to USP XXI paddle method at 50 or 100 rpm is between 6-24 hours for at least 80% of the Chromium Picolinate content, said formulation comprising spherical or irregular particles of Chromium Picolinate coated with a mixed polymer film comprising a water soluble polymer and a water insoluble polymer in a ratio that produces a substantially zero order linear release pattern of active ingredient, wherein the Chromium Picolinate content is between 1 to 80% on a weight/weight basis.
Claim 3
Dependent Claim
48 words
A formulation according to claim 1 characterized in that it consists of Chromium Picolinate coated with an adjuvant selected from the group consisting of a synthetic polymer of the polyvinyl family, the polyethylene family, the cellulose family or the polyacrylate family, fats, waxes and sugar or combinations thereof.
Claim 4
Dependent Claim
63 words
A process for the preparation of an oral formulation, according to claim 1, characterized in that Chromium Picolinate is incorporated into a carrier which releases Chromium Picolinate in a total in vitro dissolution time, determined according to the USP XXI paddle method at 50 or 100 rpm, between 6 and 24 hours for at least 80 per cent of the Chromium Picolinate content.
Claim 5
Dependent Claim
65 words
The process according to claim 3 characterized in that Chromium Picolinate is coated with an adjuvant selected from the group consisting of a synthetic polymer of the polyvinyl type, the polyethylene type or the cellulose type, fats, waxes and sugars or combinations thereof and then either compressed into tablets or processed into microcapsules/pellets which are either filled into hard gelatin capsules or compressed into tablets.
Claim 6
Dependent Claim
16 words
A controlled/extended release formulation as in claim 1, wherein the water insoluble polymer is ethyl cellulose.
Claim 7
Dependent Claim
17 words
A controlled/extended release formulation as in claim 1, wherein the water soluble polymer is hydroxypropylmethyl cellulose (HPMC).
Claim 8
Dependent Claim
37 words
A controlled/extended release formulation as in claim 1, wherein the water insoluble polymer is ethyl cellulose and the water soluble polymer is hydroxypropylmethyl cellulose (HPMC) and wherein the HPMC/ethyl cellulose ratio is substantially between 0.31 to 0.35.
Claim 9
Dependent Claim
48 words
A formulation according to claim 1 characterized in that it consists of Chromium Picolinate coated with an adjuvant selected from the group consisting of a synthetic polymer of the polyvinyl family, the polyethylene family, the cellulose family or the polyacrylate family, fats, waxes and sugar or combinations thereof.
Claim 10
Dependent Claim
48 words
A formulation according to claim 3 characterized in that it consists of Chromium Picolinate coated with an adjuvant selected from the group consisting of a synthetic polymer of the polyvinyl family, the polyethylene family, the cellulose family or the polyacrylate family, fats, waxes and sugar or combinations thereof.
Claim 11
Dependent Claim
27 words
A formulation according to claim 1 in the form of a tablet containing Chromium Picolinate embedded in polyvinyl chloride and polyvinyl acetate and magnesium stearate as lubricant.
Claim 12
Dependent Claim
27 words
A formulation according to claim 10 in the form of a tablet containing Chromium Picolinate embedded in polyvinyl chloride and polyvinyl acetate and magnesium stearate as lubricant.
Claim 13
Dependent Claim
27 words
A formulation according to claim 11 in the form of a tablet containing Chromium Picolinate embedded in polyvinyl chloride and polyvinyl acetate and magnesium stearate as lubricant.
Claim 14
Dependent Claim
63 words
A process for the preparation of an oral formulation, according to claim 2, characterized in that Chromium Picolinate is incorporated into a carrier which releases Chromium Picolinate in a total in vitro dissolution time, determined according to the USP XXI paddle method at 50 or 100 rpm, between 6 and 24 hours for at least 80 per cent of the Chromium Picolinate content.
Claim 15
Dependent Claim
44 words
A process for producing a controlled/extended release formulation of Chromium Picolinate as in claim 6 by coating Chromium Picolinate containing particles with a mixed polymer film comprising ethyl cellulose and hydroxypropylmethyl cellulose (HPMC) wherein the HPMC/ethyl cellulose ratio is substantially between 0.31 to 0.35.
Claim 16
Dependent Claim
44 words
A process for producing a controlled/extended release formulation of Chromium Picolinate as in claim 7 by coating Chromium Picolinate containing particles with a mixed polymer film comprising ethyl cellulose and hydroxypropylmethyl cellulose (HPMC) wherein the HPMC/ethyl cellulose ratio is substantially between 0.31 to 0.35.
References Cited (Backward Citations)
US4315927A
Cited
US4954492A
Cited
US4898734A
Cited
US5087623A
Cited
US5013752A
Cited
US5366990A
Cited
US5603961A
Cited
US5550113A
Cited
US5753234A
Cited
US5849338A
Cited
US5891465A
Cited
US5798101A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-12-05 | 2004-06-05 | 2004-12-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-12-05 | 2008-06-05 | 2008-12-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-12-05 | 2012-06-05 | 2012-12-05 | $7700.00 | Window Closed / Lapsed |